Avilar Therapeutics

Pioneering the discovery and development of extracellular protein degraders, a new frontier in targeted protein degradation.

[Avilar Therapeutics @Avilar_Tx]

After a recent strategic team offsite, we rolled up our sleeves and got creative on canvas. The Boston skyline never looked so good!
#AvilarGoesExtracellular

[Avilar Therapeutics @Avilar_Tx]

Patent provides broad protection for Avilar’s proprietary ASGPR-mediated extracellular protein degraders with therapeutic applications in a wide range of human diseases.
#AvailarGoesExtracellular
#patent
#proteindegradation
https://t.co/k6tRQ6p2eD

[Avilar Therapeutics @Avilar_Tx]

Congratulations to our colleagues celebrating their Avilar anniversaries in the second half of 2023.
We are grateful to have each of you on our team!
#AvilarGoesExtracellular
#Teamwork
#Team

[Avilar Therapeutics @Avilar_Tx]

Thrilled to be presenting new ATAC data that confirm key binding properties of our ASGPR ligands and characterize the relationship between ATAC PK, ATAC ligand binding properties to ASGPR and extracellular protein IgG, and ASGPR-mediated degradation.
https://t.co/BlwrcvVNbR

[Avilar Therapeutics @Avilar_Tx]

We're excited to welcome Margaret Biddle to Avilar. She brings over fifteen years of drug discovery experience and will be a key leader as we continue to discover and develop extracellular protein degraders.
#AvilarGoesExtracellular

[Avilar Therapeutics @Avilar_Tx]

Our Chief Business Officer, Adam Muzikant, Ph.D., is participating in a panel session on the year of partnership and investment resurgence at tomorrow’s Next Generation Undruggable Summit in Boston, MA.
Hope to see you there!
https://t.co/N2QjbtFGsC

[Avilar Therapeutics @Avilar_Tx]

We are excited to welcome Joel Barrish to our Board of Directors.
#AvilarGoesExtracellular

[Avilar Therapeutics @Avilar_Tx]

Lisa Molz, Ph.D., our VP of research, will present on the rapid and robust degradation of extracellular proteins with ASGPR targeting chimeras (ATACs) at this week’s Promega conference on targeted protein degradation in Madison, WI. Hope to see you there!
#AvilarGoesExtracellular

[Avilar Therapeutics @Avilar_Tx]

Excited to be presenting on Avilar’s ATAC platform for extracellular protein degradation at tomorrow's Wells Fargo Healthcare Conference in Boston.
#TPD
#AvilarGoesExtracellular

[Avilar Therapeutics @Avilar_Tx]

The Avilar team took a well-deserved break from the discovery and development of extracellular protein degraders to enjoy a river cruise and beach day on Boston’s North Shore!
#AvilarGoesExtracellular
#Team
#SummerOuting

[Avilar Therapeutics @Avilar_Tx]

Excited to be included in a review article in Chemical Society Reviews that highlights our ATAC platform for discovery and development of extracellular protein degraders that harness the natural ASGPR protein degradation pathway.
https://t.co/l3KqWpEyOX
#AvilarGoesExtracellular

[Avilar Therapeutics @Avilar_Tx]

Congratulations to our team members celebrating Avilar anniversaries in Q2. Thank you for your hard work and dedication to our efforts to develop novel extracellular protein degraders for patients.
#AvilarGoesExtracellular
#Team

[Avilar Therapeutics @Avilar_Tx]

The Avilar team is not only skilled at developing protein degraders for extracellular targets, but they also displayed some impressive bowling talent at a recent team-building event.
#AvilarGoesExtracellular #team

[Avilar Therapeutics @Avilar_Tx]

Hope to see you at today's Drug Discovery Chemistry meeting where Kevin will present our novel approach and platform for extracellular protein degradation with our ATACs (ASGPR-Targeting Chimeras), a new class of protein degraders.
#AvilarGoesExtracellular
https://t.co/ibMUf1gOE7

[Avilar Therapeutics @Avilar_Tx]

Excited to have our ATAC extracellular protein degradation platform featured in GEN. The platform has broad applicability for a wide range of diseases driven by pathogenic extracellular proteins.
#AvilarGoesExtracellular
https://t.co/iy5PcCoBeh

[Avilar Therapeutics @Avilar_Tx]

Join us in welcoming Heather to Avilar! We are thrilled to have her aboard.
https://t.co/vI7eIrpBzR

[Avilar Therapeutics @Avilar_Tx]

Today, we are joining the world to celebrate the social, economic, cultural, political, and of course, scientific achievements of women.
#IWD2023 #EmbraceEquity

[Avilar Therapeutics @Avilar_Tx]

Today we are celebrating our amazing team members at Avilar. Because of each of you, we are pioneering the next frontier in protein degradation, targeting disease-causing extracellular proteins with our novel degraders.
#EmployeeAppreciationDay
#AvilarGoesExtracellular

[Avilar Therapeutics @Avilar_Tx]

Our CSO @Effie Tozzo was interviewed about our approach which harnesses a natural process for degrading extracellular proteins, opening the potential to address traditionally undruggable targets in autoimmune, neurological, and other diseases.
https://t.co/hSEmyYsA5T

[Avilar Therapeutics @Avilar_Tx]

Today, we announced $35 million in new financing which will be used to advance multiple pipeline programs targeting extracellular proteins.
#AvilarGoesExtracellular
https://t.co/UCbppiVQjv